Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus.

Ito Y, Van Schyndle J, Nishimura T, Sugitani T, Kimura T.

Diabetes Ther. 2019 Dec;10(6):2219-2231. doi: 10.1007/s13300-019-00708-w. Epub 2019 Oct 15.

2.

Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan.

Ito Y, Van Schyndle J, Nishimura T, Sugitani T, Kimura T.

Diabetes Ther. 2019 Apr;10(2):549-562. doi: 10.1007/s13300-019-0577-7. Epub 2019 Feb 7.

3.

Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014-2017).

Ito Y, Van Schyndle J, Nishimura T, Sugitani T, Kimura T.

Diabetes Ther. 2019 Dec;10(6):2233-2249. doi: 10.1007/s13300-019-00710-2. Epub 2019 Oct 18.

4.

Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i).

Brunton S, Rozjabek HM, Pilon D, Lafeuille MH, Kamstra R, Wynant W, Bookhart BK, Lefebvre P.

Curr Med Res Opin. 2019 Apr 9:1-8. doi: 10.1080/03007995.2019.1605160. [Epub ahead of print]

PMID:
30964362
5.

Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.

Thewjitcharoen Y, Yenseung N, Malidaeng A, Nakasatien S, Chotwanvirat P, Krittiyawong S, Wanothayaroj E, Himathongkam T.

Diabetol Metab Syndr. 2017 Dec 1;9:96. doi: 10.1186/s13098-017-0297-y. eCollection 2017.

6.

Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) - A Prospective Real-world Setting Study.

Gill HK, Kaur P, Mahendru S, Mithal A.

Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):50-55. doi: 10.4103/ijem.IJEM_566_18.

7.

Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.

Goldenberg RM.

Clin Ther. 2017 Dec;39(12):2438-2447. doi: 10.1016/j.clinthera.2017.10.016. Epub 2017 Nov 22.

PMID:
29174215
8.

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.

Clegg LE, Heerspink HJL, Penland RC, Tang W, Boulton DW, Bachina S, Fox RD, Fenici P, Thuresson M, Mentz RJ, Hernandez AF, Holman RR.

Diabetes Care. 2019 Feb;42(2):318-326. doi: 10.2337/dc18-1871. Epub 2018 Dec 6.

PMID:
30523029
9.
10.
11.

Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes.

Miyoshi H, Kameda H, Yamashita K, Nakamura A, Kurihara Y.

J Diabetes Investig. 2019 Nov;10(6):1510-1517. doi: 10.1111/jdi.13064. Epub 2019 May 17.

12.

Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.

Chow W, Miyasato G, Kokkotos FK, Bailey RA, Buysman EK, Henk HJ.

Clin Ther. 2016 Sep;38(9):2071-82. doi: 10.1016/j.clinthera.2016.07.168. Epub 2016 Sep 3.

PMID:
27596020
13.

Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?

Suissa S.

Diabetes Care. 2018 Jan;41(1):6-10. doi: 10.2337/dc17-1223.

PMID:
29263192
14.

Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.

Wang L, Voss EA, Weaver J, Hester L, Yuan Z, DeFalco F, Schuemie MJ, Ryan PB, Sun D, Freedman A, Alba M, Lind J, Meininger G, Berlin JA, Rosenthal N.

Pharmacoepidemiol Drug Saf. 2019 Dec;28(12):1620-1628. doi: 10.1002/pds.4887. Epub 2019 Aug 27.

PMID:
31456304
15.

HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.

Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P.

Endocr Pract. 2018 Mar;24(3):273-287. doi: 10.4158/EP-2017-0066.

PMID:
29547044
16.
17.

Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.

Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y.

Clin Ther. 2016 Jan 1;38(1):66-88.e20. doi: 10.1016/j.clinthera.2015.10.025. Epub 2015 Dec 22.

18.

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.

Woo V, Bell A, Clement M, Noronha L, Tsoukas MA, Camacho F, Traina S, Georgijev N, Culham MD, Rose JB, Rapattoni W, Bajaj HS.

Diabetes Obes Metab. 2019 Mar;21(3):691-699. doi: 10.1111/dom.13573. Epub 2018 Dec 5.

19.

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.

Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, Nishimura H, Suzuki T, Miyamoto F, Kajiwara K, Jinnouchi T.

J Atheroscler Thromb. 2018 Jun 1;25(6):467-476. doi: 10.5551/jat.40873. Epub 2017 Dec 8.

20.

Clinical profile of patients with type 2 diabetes mellitus treated with sodium- glucose cotransporter-2 inhibitors and experience in real-world clinical practice in Spain.

Cuatrecasas G, Goñi-Goicoechea F.

Med Clin (Barc). 2016 Nov;147 Suppl 1:30-34. doi: 10.1016/S0025-7753(17)30623-1. English, Spanish.

PMID:
28760223

Supplemental Content

Support Center